Wockhardt to exit US generics business, files for voluntary liquidation of two subsidiaries
Wockhardt has announced a strategic shift in its operations in the United States, deciding to exit the generics pharmaceutical segment in the country. The company has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its two Delaware-incorporated step-down subsidiaries—Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This move marks a…






